EUCTR2010-021062-29-IT进行中（未招募）不适用
Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIO
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age = 10 years • Male or female patients with ß-thalassemia major or DBA or congenital sideroblastic anemia on chronic transfusion therapy • Myocardial T2* value that is = 5 and < 10 ms • LVEF = 56 % as determined by MRI • LIC = 7 mg Fe / g dw, as determined by R2 MRI. • Lifetime history of at least 50 units of red blood cell transfusions, and must be receiving at least = 8 units/yr of red blood cell transfusions • Serum ferritin = 1000 ng/mL • Written informed consent obtained prior to any screening procedures
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with clinical symptoms of cardiac dysfunction (shortness of breath at rest or exertion, orthopnea, exercise intolerance, lower extremity edema, arrhythmias) • Patients unable to undergo study assessments including MRI, who are claustrophobic to MRI; have a pacemaker, ferromagnetic metal implants other than those approved as safe for use in MRI scanners (e.g., some types of aneurysm clips, shrapnel in proximity to vital organs such as the retina); are obese (exceeding the equipment limits) • Patients with serum creatinine ?ULN or with significant proteinuria as indicated by a urinary protein/creatinine ratio (UPCR) = 1.0 mg/mg in a non-first void urine sample at baseline • Patients with ALT (SGPT) levels >5 x ULN only if their LIC is <10 mg Fe/g dw • Patients with considerable impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral deferasirox / ICL670 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) • Significant medical condition interfering with the ability to partake in this study (e.g.uncontrolled hypertension, systemic cardiovascular, renal, hepatic disease, etc.) • Patients with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption • History of hypersensitivity to any of the study drugs or their excipients • History of clinically relevant ocular and/or auditory toxicity related to iron chelation therapy • Patients with psychiatric or addictive disorders which prevent them from giving their informed consent or undergoing any of the treatment options or patients unwilling or unable to comply with the protocol • Patients with a known history of HIV seropositivity (Elisa or Western blot) • History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin or cervical carcinoma in situ • Pregnant or nursing (lactating) women are not eligible to participate in the study. Females of reproductive potential must be willing during the entire study period to use one or more of the following acceptable methods of contraception, namely: i) surgical sterilization (e.g., bilateral tubal ligation, vasectomy), ii) hormonal contraception (implantable, patch, oral), and iii) double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap) • Patients participating in another clinical trial and receiving an investigational drug • Patients who are considered potentially unreliable and/or not cooperative, unwilling or unable to comply with the protocol
研究者
相似试验
进行中（未招募）
不适用
Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIOtransfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overloadMedDRA version: 13.1Level: LLTClassification code 10065974Term: Chronic iron overloadSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-021062-29-GRovartis Pharma Services AG45
尚未招募
2 期
Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-20202024-519106-12-00G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica33
进行中（未招募）
不适用
Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIOEUCTR2010-021062-29-GBovartis Pharma Services AG45
进行中（未招募）
1 期
International multicenter study to test the use of 3 combined targeted therapy drugs for Colorectal cancer (encorafenib, binimetinib and cetuximab) in subjects with mutant Metastatic Colorectal CancerBRAF V600E -mutant Metastatic Colorectal CancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2018-000271-32-GBPierre Fabre Médicament90
已完成
2 期
Phase II, open-label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAF V600E -mutant Metastatic Colorectal CancerNL-OMON50375Pierre Fabre10